As per the research groups listed in Thomson Reuters survey, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), the stock can touch mean price target of $140.33 in coming period. This price target highlights the recommendations of leading experts in the market.
Thomson Reuters studies the brokerages research reports to reach this price target. The latest poll indicate that the company may record earnings of $1.32 per share in looming quarter and $3.45 during current fiscal.
While evaluating Ligand Pharmaceuticals Incorpor on the technical side, it is seen that the firm’s shares price is trading $-7.08 points away or -6.01% from its 50-day moving average of $117.90. Further it is trading $-4.42 or -3.83% away its 200-day moving average of $115.24. MA here stands for moving average.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock made a high of $139.79 in last 12-months while the lowest level in same period was $79.66. It entails if stock price makes a movement of over $-28.97, it will make a new 52-week high. In the case of +39.12% decline, it will touch a new 52-week low.
The valuation of Ligand Pharmaceuticals Incorpor is done by analysts by using price-to-earnings ratio. This ratio considers the latest price and profits for valuating a stock. The ratio is calculated by dividing stock price by annual EPS. For now, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) P/E ratio is 10.45. The stakeholders can further gauge a firm’s performance by calculating Price-to-Earnings-Growth ratio, and for Ligand Pharmaceuticals Incorpor it stands at 0.73.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...